started · updated
Onconic Therapeutics unveils OCN-501 for muscle-preserving obesity treatment
Onconic Therapeutics has unveiled the research direction for its next-generation drug candidate, OCN-501. The candidate is being developed as a first-in-class treatment designed to be used in combination with GLP-1 receptor agonists, such as semaglutide, to address the issue of muscle loss during weight reduction.
Unlike traditional weight loss drugs that compete directly with existing GLP-1 therapies, OCN-501 aims to complement them by focusing on the 'quality of weight loss.' This strategy targets the preservation of skeletal muscle and the improvement of body composition, addressing a significant unmet need in the obesity treatment market.
The research has been selected for a late-breaking abstract and an oral presentation at the upcoming ObesityWeek 2026 conference. Detailed research methodologies and data are scheduled to be presented this November in Washington, D.C.
Entities
Eli Lilly · Onconic Therapeutics · The Obesity Society · Washington, D.C.
Claims
What the coverage asserts, and how many sources carry each claim.
- [● 3 SOURCES] OCN-501 is being developed as a combination therapy rather than a replacement for existing GLP-1 weight loss drugs. www.biotimes.co.kr · www.hin.company · www.thebionews.net
- [● 3 SOURCES] OCN-501 is designed to be used in combination with GLP-1 class obesity treatments to preserve skeletal muscle during weight loss. www.biotimes.co.kr · www.hin.company · www.thebionews.net
- [● 3 SOURCES] Onconic Therapeutics has revealed the research direction for its next-generation drug candidate, OCN-501. www.biotimes.co.kr · www.hin.company · www.thebionews.net
- [● 3 SOURCES] Detailed research data and results will be presented in November at the ObesityWeek conference in Washington, D.C. www.biotimes.co.kr · www.hin.company · www.thebionews.net
- [● 3 SOURCES] The Obesity Society selected OCN-501 research for a late-breaking abstract and an oral presentation at ObesityWeek 2026. www.biotimes.co.kr · www.hin.company · www.thebionews.net
- [● 3 SOURCES] The Obesity Society selected the OCN-501 research for a late-breaking abstract and an oral presentation at ObesityWeek 2026. www.biotimes.co.kr · www.hin.company · www.thebionews.net
- [● 3 SOURCES] OCN-501 is being developed as a first-in-class candidate to be used in combination with GLP-1 weight loss drugs. www.biotimes.co.kr · www.hin.company · www.thebionews.net
- [● 3 SOURCES] Detailed research methods and data will be disclosed in November at the ObesityWeek conference in Washington, D.C. www.biotimes.co.kr · www.hin.company · www.thebionews.net
- [● 3 SOURCES] The research aims to preserve skeletal muscle during the weight loss process caused by semaglutide. www.biotimes.co.kr · www.hin.company · www.thebionews.net